Current standard-of-care treatment options for this stage of prostate cancer progression include different chemotherapeutic agents such as docetaxel and cabazitaxel, the androgen receptor signal inhibitors (ARSIs) abiraterone and enzalutamide, and radionuclides (Radium-223)3–7. This evidence concerns the gene AR and prostate carcinoma.